A ransomware attack that takes down a 50,000-person pharmaceutical company makes the news. The same attack on a 30-person biotech is just as devastating — often more so — but it never makes the news because the company didn't survive to tell the story.
Early-stage biotech companies are not too small to be targets. In fact, they're often targeted specifically because they have valuable IP and limited security controls. Here's what the security controls that actually matter look like at the early stage.
What large pharma does that you should too
Endpoint detection and response (EDR)
Every laptop and workstation in a properly secured environment has an EDR agent installed. Unlike traditional antivirus, EDR doesn't just look for known malware signatures — it monitors system behavior in real time, flags anomalies, and can isolate a compromised machine from the network within seconds of detection.
CrowdStrike, SentinelOne, and Microsoft Defender for Endpoint are the main enterprise players. For a 20-30 person biotech, MDR for Business (Managed Detection and Response) packages from these vendors cost $10-20 per endpoint per month and provide 24/7 monitoring without needing an in-house security team.
Multi-factor authentication on everything
The single most effective security control against credential-based attacks is MFA. Not optional MFA. Enforced, phishing-resistant MFA on every system that matters: email, ELN, LIMS, cloud infrastructure, VPN, and administrative access to any system.
Large pharma companies enforce this. Many early-stage biotechs leave it optional. "Optional" means "not enabled on the account that gets compromised."
Privileged access management
Administrator accounts — the ones with access to everything — should be used only for administrative tasks, and those tasks should be logged. Nobody should be running their daily work from an administrator account. This limits blast radius when credentials are compromised.
What can wait at the early stage
Not everything on the enterprise security checklist is appropriate for a 15-person company. Here's what you can defer without meaningful risk:
- A full Security Operations Center (SOC). This is what MDR services replace at a fraction of the cost.
- Network segmentation beyond basics. Separating guest WiFi from corporate is enough until you're operating clinical infrastructure.
- Bug bounty programs. Save this for when you have a publicly accessible product or API.
- Full penetration testing. A vulnerability scan and basic security assessment is sufficient until you have significant external-facing systems or are preparing for SOC 2.
The ransomware scenario nobody wants to think about
Ransomware in a biotech context isn't just an IT problem — it's a business continuity crisis. If the attack hits your ELN and instrument data, you may not be able to continue ongoing studies. If it hits your network drives and you don't have tested backups, that data may be unrecoverable.
The average ransomware recovery time for a small company without proper backups and incident response procedures is 23 days. For a company in the middle of an IND submission or clinical trial, 23 days of downtime is catastrophic.
The three things that most dramatically reduce ransomware impact are: tested offline backups, network segmentation to limit lateral movement, and an incident response plan that someone has actually read. None of these require a large IT budget. They require preparation.
The compliance angle
If you're pursuing SOC 2 Type II (increasingly required by pharma partners and hospital systems before signing), many of these controls are not optional — they're required by the Trust Services Criteria. Starting them early means you're building toward compliance rather than retrofitting for it.
Similarly, if you're handling Protected Health Information (PHI) from clinical trials, HIPAA Security Rule requirements overlap significantly with these controls. Getting the fundamentals right serves both regulatory and business purposes.
Questions about your IT environment? Schedule a free assessment →